MX2007001114A - Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano. - Google Patents
Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.Info
- Publication number
- MX2007001114A MX2007001114A MX2007001114A MX2007001114A MX2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A MX 2007001114 A MX2007001114 A MX 2007001114A
- Authority
- MX
- Mexico
- Prior art keywords
- ckd
- lanthanum hydroxycarbonate
- hyperphosphataemia
- suffering
- susceptible
- Prior art date
Links
- NKCVNYJQLIWBHK-UHFFFAOYSA-N carbonodiperoxoic acid Chemical compound OOC(=O)OO NKCVNYJQLIWBHK-UHFFFAOYSA-N 0.000 title abstract 2
- 201000005991 hyperphosphatemia Diseases 0.000 title abstract 2
- 229910052746 lanthanum Inorganic materials 0.000 title abstract 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 title abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 4
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002037 soft tissue calcification Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59110504P | 2004-07-27 | 2004-07-27 | |
| PCT/US2005/026668 WO2006015055A1 (en) | 2004-07-27 | 2005-07-27 | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007001114A true MX2007001114A (es) | 2007-07-11 |
Family
ID=35787449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007001114A MX2007001114A (es) | 2004-07-27 | 2005-07-27 | Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060153932A1 (https=) |
| EP (1) | EP1708723A4 (https=) |
| JP (1) | JP4869229B2 (https=) |
| KR (2) | KR20070054191A (https=) |
| CN (1) | CN101018555A (https=) |
| AU (1) | AU2005269362B2 (https=) |
| BR (1) | BRPI0513603A (https=) |
| CA (1) | CA2574450C (https=) |
| EA (1) | EA010980B1 (https=) |
| MX (1) | MX2007001114A (https=) |
| NO (1) | NO20070906L (https=) |
| NZ (1) | NZ552861A (https=) |
| WO (1) | WO2006015055A1 (https=) |
| ZA (1) | ZA200701707B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
| EP1660104B1 (en) * | 2003-08-26 | 2010-03-10 | Shire Holdings AG | Pharmaceutical formulation comprising lanthanum compounds |
| JP2008516971A (ja) * | 2004-10-15 | 2008-05-22 | アルテアーナノ，インコーポレーテッド | 錠剤による負荷が軽減されるリン酸塩結合剤 |
| AU2006279343A1 (en) * | 2005-08-17 | 2007-02-22 | Altairnano, Inc. | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
| US20070104799A1 (en) * | 2005-11-09 | 2007-05-10 | Shire International Licensing B.V. | Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds |
| JP2009525277A (ja) * | 2006-01-30 | 2009-07-09 | グロボアジア エルエルシー | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| EP1852695B1 (en) * | 2006-05-05 | 2011-10-26 | Shire International Licensing B.V. | Assay for lanthanum hydroxy carbonate |
| ES2871021T3 (es) | 2010-05-12 | 2021-10-28 | Spectrum Pharmaceuticals Inc | Hidróxido de carbonato de lantano, oxicarbonato de lantano y procedimientos de fabricación y uso |
| US8263119B2 (en) | 2010-12-01 | 2012-09-11 | Shire Llc | Capsule formulations containing lanthanum compounds |
| US8697132B2 (en) | 2010-12-01 | 2014-04-15 | Shire Llc | Capsule and powder formulations containing lanthanum compounds |
| GB201501000D0 (en) * | 2015-01-21 | 2015-03-04 | Univ Edinburgh | Lanthanum thiosulfate and methods of preparation of the same |
| US20190381024A1 (en) * | 2015-10-27 | 2019-12-19 | Medice Arzneimittel Putter Gmbh & Co. Kg | Nicotinamide for lowering phosphate levels in hyperphosphatemia |
| US10835461B2 (en) | 2015-12-01 | 2020-11-17 | Bae Yong Kim | Bio-active material composite, preparing method thereof and cosmetic composition containing the same |
| KR101684289B1 (ko) | 2016-05-17 | 2016-12-09 | 한국식품연구원 | 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품 |
| US10322409B1 (en) | 2018-03-05 | 2019-06-18 | King Fahd University Of Petroleum And Minerals | Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4592082A (en) * | 1984-08-10 | 1986-05-27 | The United States Of America As Represented By The United States Department Of Energy | Quantitative determination of mineral composition by powder X-ray diffraction |
| CA2117351C (en) * | 1992-01-13 | 1998-03-03 | Julian Belknap Lo | Preparation of tablets of increased strength |
| US5562921A (en) * | 1994-07-15 | 1996-10-08 | Sherman; Bernard C. | Stable solid pharmaceutical compositions containing enalapril maleate |
| US5435986A (en) * | 1994-08-30 | 1995-07-25 | Industrial Technology Research Institute | Method for preparing high purity aluminum hydroxide |
| GB9506126D0 (en) * | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
| GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| CA2381713A1 (en) * | 1999-09-02 | 2001-03-08 | Big Bear Bio, Inc. | Methods and compositions for reducing serum phosphate levels |
| US6160016A (en) * | 1999-12-22 | 2000-12-12 | Wisconsin Alumni Research Foundation | Phosphorus binder |
| GB0015745D0 (en) * | 2000-06-27 | 2000-08-16 | Shire Holdings Ag | Treatment of bone diseases |
| KR100956013B1 (ko) * | 2001-04-23 | 2010-05-06 | 샤이어 인터내쇼날 라이센싱 비.브이. | 희토류 화합물을 포함하는 신장 결석 질환 치료용 약제학적 조성물 |
| US7469036B2 (en) * | 2002-04-19 | 2008-12-23 | Los Alamos National Security, Llc | Analysis of macromolecules, ligands and macromolecule-ligand complexes |
| WO2003094933A2 (en) * | 2002-05-08 | 2003-11-20 | Shire Holding Ag | Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
| US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| US7381428B2 (en) * | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
| EP1660104B1 (en) * | 2003-08-26 | 2010-03-10 | Shire Holdings AG | Pharmaceutical formulation comprising lanthanum compounds |
-
2005
- 2005-07-27 KR KR1020077004213A patent/KR20070054191A/ko not_active Ceased
- 2005-07-27 US US11/191,600 patent/US20060153932A1/en not_active Abandoned
- 2005-07-27 JP JP2007523773A patent/JP4869229B2/ja not_active Expired - Fee Related
- 2005-07-27 AU AU2005269362A patent/AU2005269362B2/en not_active Ceased
- 2005-07-27 KR KR1020097001877A patent/KR101072196B1/ko not_active Expired - Fee Related
- 2005-07-27 EP EP05775640A patent/EP1708723A4/en not_active Withdrawn
- 2005-07-27 EA EA200700273A patent/EA010980B1/ru not_active IP Right Cessation
- 2005-07-27 CA CA2574450A patent/CA2574450C/en not_active Expired - Fee Related
- 2005-07-27 BR BRPI0513603-2A patent/BRPI0513603A/pt not_active IP Right Cessation
- 2005-07-27 WO PCT/US2005/026668 patent/WO2006015055A1/en not_active Ceased
- 2005-07-27 CN CNA2005800309851A patent/CN101018555A/zh active Pending
- 2005-07-27 MX MX2007001114A patent/MX2007001114A/es unknown
- 2005-07-27 NZ NZ552861A patent/NZ552861A/en not_active IP Right Cessation
-
2007
- 2007-02-16 NO NO20070906A patent/NO20070906L/no not_active Application Discontinuation
- 2007-02-27 ZA ZA200701707A patent/ZA200701707B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101018555A (zh) | 2007-08-15 |
| KR101072196B1 (ko) | 2011-10-10 |
| NZ552861A (en) | 2010-11-26 |
| EP1708723A4 (en) | 2006-12-20 |
| EA010980B1 (ru) | 2008-12-30 |
| AU2005269362A1 (en) | 2006-02-09 |
| KR20070054191A (ko) | 2007-05-28 |
| NO20070906L (no) | 2007-04-23 |
| EP1708723A1 (en) | 2006-10-11 |
| JP2008508297A (ja) | 2008-03-21 |
| EA200700273A1 (ru) | 2007-08-31 |
| US20060153932A1 (en) | 2006-07-13 |
| CA2574450C (en) | 2011-07-19 |
| BRPI0513603A (pt) | 2008-05-13 |
| CA2574450A1 (en) | 2006-02-09 |
| ZA200701707B (en) | 2008-10-29 |
| AU2005269362B2 (en) | 2010-08-12 |
| JP4869229B2 (ja) | 2012-02-08 |
| KR20090023743A (ko) | 2009-03-05 |
| WO2006015055A1 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007001114A (es) | Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano. | |
| CY1120022T1 (el) | Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| WO2007124461A3 (en) | Glp-1 compounds | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| WO2007087468A3 (en) | Adiponectin for treatment of various disorders | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| EP2628486A3 (en) | Method for treating bone fracture with anti-sclerostin antibodies | |
| EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
| WO2007009894A3 (en) | Peptides for use in the treatment of obesity | |
| UA100111C2 (ru) | Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона | |
| EP3276004A3 (en) | Methods for treating chronic kidney disease | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| NO20082536L (no) | Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser | |
| WO2008043052A3 (en) | Human antibodies neutralizing human metapneumovirus | |
| WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
| WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
| WO2006048450A3 (en) | Peptides for use in the treating obesity | |
| WO2006048452A3 (en) | Peptides for use in treating of obesity | |
| WO2003094933A3 (en) | Use of lanthanum for the treatment of hypercalcemia and bone metastasis | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| TW200742580A (en) | Methods for treating nephrolithiasis | |
| WO2007014253A3 (en) | Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure | |
| WO2006138043A3 (en) | Method and compositions for the treatment of diabetes and related complications | |
| WO2008019388A3 (en) | Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome |